Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 10/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | HMOX1 | P09601 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | BTK | Q06187 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12448279 | 1.00 | MEN1 (0.36) | MEN1ALDH1A1KMT2ADPP4DPP7 | |
| SCHEMBL12448278 | 1.00 | MEN1 (0.36) | MEN1ALDH1A1KMT2ADPP4DPP7 | |
| SCHEMBL20934784 | 1.00 | MEN1 (0.36) | MEN1ALDH1A1KMT2ADPP4DPP7 | |
| SCHEMBL17306184 | 1.00 | MEN1 (0.36) | MEN1ALDH1A1KMT2ADPP4DPP7 | |
| SCHEMBL17306170 | 1.00 | MEN1 (0.36) | MEN1ALDH1A1KMT2ADPP4DPP7 | |
| SCHEMBL16131147 | 1.00 | MEN1 (0.36) | MEN1ALDH1A1KMT2ADPP4DPP7 | |
| SCHEMBL17660709 | 0.90 | DPP4 (0.38) | ALDH1A1DPP4DPP7PDE4BBTK | |
| SCHEMBL17660711 | 0.90 | DPP4 (0.38) | ALDH1A1DPP4DPP7PDE4BBTK | |
| SCHEMBL10328208 | 0.89 | ALDH1A1 (0.42) | MEN1ALDH1A1KMT2ADPP4DPP7 | |
| SCHEMBL20929383 | 0.89 | ALDH1A1 (0.42) | MEN1ALDH1A1KMT2ADPP4DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3517536-B1 | AMINOTRIAZINE DERIVATIVES USEFUL AS TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES INC (US) | 2021-05-05 | — | — | EP | disclosed |
| EP-3517536-A1 | AMINOTRIAZINE DERIVATIVES USEFUL AS TANK-BINDING KINASE INHIBITOR COMPOUNDS | Gilead Sciences, Inc. (US) | 2019-07-31 | — | — | EP | disclosed |
| US-20190016717-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2019-01-17 | — | — | US | disclosed |
| US-10040781-B2 | Tank-binding kinase inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-20160096827-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2016-04-07 | — | — | US | disclosed |
| US-20150344473-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2015-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344473-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | TBKBP1, TNKS1BP1, TNKS | MEN1 3091/4885ALDH1A1 4260/4885KMT2A 1865/4885 |
| US-10040781-B2 | Tank-binding kinase inhibitor compounds | TBKBP1, TNKS1BP1, TNKS | MEN1 3091/4885ALDH1A1 4260/4885KMT2A 1865/4885 |
| US-20190016717-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | TBKBP1, TNKS1BP1, TNKS | MEN1 3091/4885ALDH1A1 4260/4885KMT2A 1865/4885 |
| US-20160096827-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | TBKBP1, TNKS1BP1, TNKS | MEN1 3091/4885ALDH1A1 4260/4885KMT2A 1865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.